Nautilus Biotechnology, Inc. (CIK: 0001808805) EDGAR, Information, Filings... CompaniesBIO.Com

Nautilus Biotechnology, Inc.

Mailing address
2701 EASTLAKE AVE EAST, SEATTLE, Delaware, 98102
Phone
206-333-2001
State location
Washington
State of incorporation
Delaware
Fiscal year end
December 31
SIC
3826 - (CF Office: Office of Life Sciences) LABORATORY ANALYTICAL INSTRUMENTS
Filings
N/A

Nautilus Biotechnology, Inc. (CIK: 0001808805) is an American company incorporated in the state of Washington. Head office is located at 2701 EASTLAKE AVE EAST, SEATTLE, Washington, 98102. Work in the industry 3826 - (CF Office: Office of Life Sciences) LABORATORY ANALYTICAL INSTRUMENTS. Nautilus Biotechnology, Inc. is a public company and trade via Over-The-Counter (OTC).

Old names:

ARYA Sciences Acquisition Corp III from 2020-17-Apr to 2021-08-Jun

Owner	Filings	Transaction Date	Type of Owner
ALTMAN MICHAEL SETH	0001746738	Jun-15-2023	director
Godwin Mary E.	0001439716	Jul-01-2022	officer: Senior VP, Operations
Weld Gwen E	0001378831	Apr-11-2022	officer: Chief People Officer
Akinsanya Karen	0001797672	Mar-30-2022	director
EDELMAN JOSEPH	0001164426	Dec-08-2021	10 percent owner
PERCEPTIVE ADVISORS LLC	0001224962	Dec-08-2021	director
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD	0001249675	Dec-08-2021	10 percent owner
McIlwain Matthew S	0001381752	Aug-24-2021	director
Andreessen Marc L	0001160077	Jun-09-2021	10 percent owner
HOROWITZ BENJAMIN A	0001166586	Jun-09-2021	10 percent owner
NAZEM FARZAD	0001234663	Jun-09-2021	director
Patel Sujal M	0001378830	Jun-09-2021	director, 10 percent owner, officer: CEO, President, and Secretary
Posard Matthew L.	0001543792	Jun-09-2021	director
AH Bio Fund II-B, L.P.	0001725720	Jun-09-2021	10 percent owner
AH Bio Fund II, L.P.	0001725721	Jun-09-2021	10 percent owner
AH Equity Partners Bio II, L.L.C.	0001725722	Jun-09-2021	10 percent owner
Epperly Melissa B,	0001807359	Jun-09-2021	director
Andreessen Horowitz LSV Fund II, L.P.	0001829357	Jun-09-2021	10 percent owner
AH Equity Partners LSV II, L.L.C.	0001829384	Jun-09-2021	10 percent owner
Andreessen Horowitz LSV Fund II-Q, L.P.	0001829458	Jun-09-2021	10 percent owner
Andreessen Horowitz LSV Fund II-B, L.P.	0001829459	Jun-09-2021	10 percent owner
Pande Vijay Satyanand	0001840663	Jun-09-2021	director
Sankar Subramanian	0001856744	Jun-09-2021	officer: Senior VP, Product Development
Mowry Anna	0001856938	Jun-09-2021	officer: CFO and Treasurer
Nelson Nicholas A.	0001857944	Jun-09-2021	officer: CBO & Senior VP, Bus. Dev.
Mallick Parag	0001857948	Jun-09-2021	director, 10 percent owner, officer: Chief Scientist
Murphy Matthew B.	0001865778	Jun-09-2021	officer: General Counsel
Campbell Bradley L	0001400971	Aug-06-2020	director
Islam Saqib	0001575408	Aug-06-2020	director
Wider Todd	0001642715	Aug-06-2020	director
Poukalov Konstantin	0001678736	Aug-06-2020	officer: Chief Business Officer
Stone Adam Leo	0001727440	Aug-06-2020	director, 10 percent owner, officer: Chief Executive Officer
ARYA Sciences Holdings III	0001808802	Aug-06-2020	10 percent owner

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Nautilus Biotechnology, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0002037191-25-000004 ( Act) Size: 0 KB	Nov-10-2025
8-K	Document	Current report filing Acc-no: 0001808805-25-000082 (34 Act) Size: KB	Nov-04-2025	001-39434 251445396
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001808805-25-000080 (34 Act) Size: KB	Oct-28-2025	001-39434 251424921
8-K	Document	Current report filing Acc-no: 0001808805-25-000077 (34 Act) Size: KB	Oct-28-2025	001-39434 251420826
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001378830-25-000003 ( Act) Size: 0 KB	Sep-09-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001865778-25-000003 ( Act) Size: 0 KB	Sep-05-2025
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001808805-25-000072 (34 Act) Size: KB	Jul-31-2025	001-39434 251172207
8-K	Document	Current report filing Acc-no: 0001808805-25-000069 (34 Act) Size: KB	Jul-31-2025	001-39434 251168800
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001808805-25-000064 ( Act) Size: 0 KB	Jun-25-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001808805-25-000063 ( Act) Size: 0 KB	Jun-25-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001808805-25-000062 ( Act) Size: 0 KB	Jun-25-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001808805-25-000061 ( Act) Size: 0 KB	Jun-25-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001808805-25-000060 ( Act) Size: 0 KB	Jun-25-2025
SCHEDULE 13D/A	Document	Acc-no: 0001104659-25-062136 (34 Act) Size: KB	Jun-24-2025	005-91615 251069762
8-K	Document	Current report filing Acc-no: 0001808805-25-000054 (34 Act) Size: KB	Jun-23-2025	001-39434 251065342
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001808805-25-000051 ( Act) Size: 0 KB	Jun-02-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001808805-25-000049 ( Act) Size: 0 KB	May-12-2025
8-K	Document	Current report filing Acc-no: 0001808805-25-000047 (34 Act) Size: KB	May-02-2025	001-39434 25909126
ARS	Document	Annual report to security holders Acc-no: 0001808805-25-000045 (34 Act) Size: KB	Apr-29-2025	001-39434 25887606
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001808805-25-000044 (34 Act) Size: KB	Apr-29-2025	001-39434 25887241

Recent 20 filings. View all Nautilus Biotechnology, Inc. filings

Overall rating 5.0

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Nautilus Biotechnology, Inc. overview
Nautilus Biotechnology, Inc. job
Nautilus Biotechnology, Inc. stock
Nautilus Biotechnology, Inc. ownership
Nautilus Biotechnology, Inc. CEO
Nautilus Biotechnology, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.